The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus

Aim: We evaluated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for their use with other glucose-lowering drugs and drugs for the treatment of type 2 diabetes mellitus (T2DM), in a standard-of-care regimen with maximum tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmen, Teodor, Bobirca, Florin-Teodor, Bica, Ioana-Cristina, Mihai, Doina-Andrada, Pop, Corina, Stoian, Anca Pantea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051290/
https://www.ncbi.nlm.nih.gov/pubmed/36983994
http://dx.doi.org/10.3390/life13030839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051290/
https://www.ncbi.nlm.nih.gov/pubmed/36983994
http://dx.doi.org/10.3390/life13030839

Ejemplares similares